J&J Drug Combo Shows Promise in Treating Lung Cancer
Johnson & Johnson's Rybrevant became the first medication for a particular subset of non-small cell lung cancer (NSCLC) in 2021.
Source: hngn.com
Stay updated with breaking news from Halts Litigations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Johnson & Johnson's Rybrevant became the first medication for a particular subset of non-small cell lung cancer (NSCLC) in 2021.
Johnson & Johnson's Rybrevant became the first medication for a particular subset of non-small cell lung cancer (NSCLC) in 2021.
A US jury ordered Johnson & Johnson to pay $18.8 million to a California man who claimed he developed cancer from their baby powder.
Canadian authorities said that the country would be considering the possibility of offering the mifepristone abortion pill if a ban of the drug in the United States pushes through.